 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Clear Harbor Asset Management LLC acquired a new stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with...

Clear Harbor Asset Management LLC Acquires Shares of 11,000 Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)

Iovance Biotherapeutics Inc (IOVA) has issued an announcement. General Merrill A. McPeak, a key figure on the Board of Directors for Iovance Biothe...

Iovance Board Changes: McPeak Retires, Vogt Nominated

This indicator may be signaling IOVA's price has momentum to move higher, since its current price moved above its price 14 days ago. Traders may consider buying the stock or exploring call options...

Iovance Biotherapeutics (IOVA, $14.8) entered Uptrend as Momentum indicator ascends above 0 level on Mar 28, 2024

It might be of some concern to shareholders to see the Iovance Biotherapeutics, Inc. ( NASDAQ:IOVA ) share price down...

Iovance Biotherapeutics (NASDAQ:IOVA) pulls back 3.5% this week, but still delivers shareholders solid 141% return over 1 year

It has been about a month since the last earnings report for Iovance Biotherapeutics (IOVA). Shares have lost about 6.9% in that time frame, underperforming the S&P 500.Will the recent negative trend...

Iovance Biotherapeutics (IOVA) Down 6.9% Since Last Earnings Report: Can It Rebound?

Investors in Iovance Biotherapeutics Inc (IOVA) saw new options begin trading today, for the May 10th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the IOVA...

May 10th Options Now Available For Iovance Biotherapeutics (IOVA)

Iovance Biotherapeutics: Initial Amtagvi Launch In Focus...

Iovance Biotherapeutics: Initial Amtagvi Launch In Focus

SAN CARLOS, Calif., March 22, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the Company ), a biotechnology company focused on innovating, developing, and...

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Iovance Biotherapeutics price target raised by $1 at Piper Sandler, here's why

Latest Ratings for IOVA
 DateFirmActionFromTo Feb 2022BairdMaintainsOutperform Feb 2022Chardan CapitalMaintainsBuy Jan 2022StifelUpgradesHoldBuy
 View More Analyst Ratings for IOVA...

Piper Sandler Maintains Overweight Rating for Iovance Biotherapeutics: Here's What You Need To Know

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.

Volume (M)	2.65M
52-Wk High	$18.33
52-Wk Low	$3.21

IOVA Iovance Biotherapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals